CVM - CEL-SCI Corporation

NYSE American - Nasdaq Real Time Price. Currency in USD
1.820
+0.050 (+2.825%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close1.770
Open1.790
Bid1.580 x 500
Ask2.000 x 2800
Day's Range1.772 - 1.850
52 Week Range0.060 - 3.690
Volume86,534
Avg. Volume187,545
Market Cap21.535M
Beta-0.33
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date1996-08-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend?
    Simply Wall St.15 days ago

    CEL-SCI Corporation’s (CVM) EPS Grew 65.7% In A Year. Was It Better Than Long-Term Trend?

    When CEL-SCI Corporation (AMEX:CVM) released its most recent earnings update (30 June 2017), I wanted to understand how these figures stacked up against its past performance. The two benchmarks IRead More...

  • Capital Cubelast month

    ETFs with exposure to CEL-SCI Corp. : November 7, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CEL-SCI Corp. Here are 5 ETFs with the largest exposure to CVM-US. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Who Owns Most Of CEL-SCI Corporation (CVM)?
    Simply Wall St.2 months ago

    Who Owns Most Of CEL-SCI Corporation (CVM)?

    In this article, I will take a quick look at CEL-SCI Corporation’s (AMEX:CVM) recent ownership structure – an unconventional investing subject, but an important one. The impact of a company’sRead More...

  • Capital Cube2 months ago

    ETFs with exposure to CEL-SCI Corp. : October 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CEL-SCI Corp. Here are 5 ETFs with the largest exposure to CVM-US. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to CEL-SCI Corp. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CEL-SCI Corp. Here are 5 ETFs with the largest exposure to CVM-US. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to CEL-SCI Corp. : September 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CEL-SCI Corp. Here are 5 ETFs with the largest exposure to CVM-US. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube3 months ago

    ETFs with exposure to CEL-SCI Corp. : August 31, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to CEL-SCI Corp. Here are 5 ETFs with the largest exposure to CVM-US. Comparing the performance and risk of CEL-SCI Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • CEL-SCI Corp. :CVM-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017
    Capital Cube4 months ago

    CEL-SCI Corp. :CVM-US: Earnings Analysis: Q3, 2017 By the Numbers : August 24, 2017

    Categories: Yahoo FinanceGet free summary analysis CEL-SCI Corp. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of CEL-SCI Corp. – Curis, Inc., BioCryst Pharmaceuticals, Inc., Amgen Inc., Xencor, Inc., CytRx Corporation, Johnson & Johnson, Vical Incorporated, Teva Pharmaceutical Industries Limited Sponsored ADR and Emergent BioSolutions Inc. ... Read more (Read more...)

  • TheStreet.com4 months ago

    Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward

    The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.

  • Associated Press4 months ago

    Cel-Sci reports 3Q loss

    On a per-share basis, the Vienna, Virginia-based company said it had a loss of 53 cents. The cancer immunotherapy company posted revenue of $17,400 in the period. Its adjusted revenue was $17,000. In the ...

  • CEL-SCI Corp. :CVM-US: Earnings Analysis: Q2, 2017 By the Numbers : June 19, 2017
    Capital Cube6 months ago

    CEL-SCI Corp. :CVM-US: Earnings Analysis: Q2, 2017 By the Numbers : June 19, 2017

    Categories: Yahoo FinanceGet free summary analysis CEL-SCI Corp. reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of CEL-SCI Corp. – Curis, Inc., BioCryst Pharmaceuticals, Inc., Amgen Inc., Xencor, Inc., CytRx Corporation, Johnson & Johnson, Vical Incorporated, Teva Pharmaceutical Industries Limited Sponsored ADR and Emergent BioSolutions Inc. ... Read more (Read more...)

  • Associated Press7 months ago

    Cel-Sci reports 2Q loss

    On a per-share basis, the Vienna, Virginia-based company said it had a loss of 5 cents. The cancer immunotherapy company posted revenue of $17,200 in the period. Its adjusted revenue was $17,000. In the ...

  • TheStreet.com7 months ago

    A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?

    Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.

  • Associated Press10 months ago

    Cel-Sci posts 1Q profit

    On a per-share basis, the Vienna, Virginia-based company said it had net income of 1 cent. The cancer immunotherapy company posted revenue of $7,300 in the period. Its adjusted revenue was $7,000. In the ...

  • Associated Presslast year

    Cel-Sci reports 4Q loss

    The Vienna, Virginia-based company said it had a loss of 1 cent per share. The cancer immunotherapy company posted revenue of $101,000 in the period. For the year, the company reported that its loss narrowed ...